Cost-Effectiveness of Nationwide HPV Vaccination in Girls in Kazakhstan: A UNIVAC-Based Analysis

This peer-reviewed article models the epidemiological impact and cost-effectiveness of nationwide HPV vaccination for girls in Kazakhstan. Using the WHO-endorsed UNIVAC tool, the study estimates the effects of a two-dose quadrivalent Gardasil-4 schedule for 10-year-old girls over 2025–2035, from governmental and societal perspectives.

Key findings

Nationwide HPV vaccination was projected to reduce HPV-related disease cases by 68.2%, from 112,198 to 35,628 cases.
Cervical cancer deaths were projected to decline by 68.3%, from 15,921 to 5,056 deaths.
The programme was estimated to avert 67,445 DALYs over the modelled period.
The ICER was estimated at US$533 per DALY averted from the governmental perspective and US$1,169 from the societal perspective.
The model projected US$42.8 million in healthcare cost savings, largely through fewer hospitalizations and outpatient visits.

How can the findings be used?

The findings can support Kazakhstan’s planning and sustainability discussions for HPV vaccine delivery, especially as the country works toward cervical cancer elimination targets. They also provide country-specific evidence for policymakers weighing vaccine programme costs against long-term savings and health gains.

Thumbnail image credit: authors

Read article

LanguageEnglish

Submit your work

Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.

Submit your work